Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SLXNW
- Price
- 0.06
- Stock movement up
- +0.00 (9.20%)
- Company name
- Biomotion Sciences Warrant
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -63.97%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-15
DIVIDENDS
SLXNW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.03 |
| Daily high | 0.03 |
| Daily low | 0.03 |
| Daily Volume | 1K |
| All-time high | 1.00 |
| 1y analyst estimate | - |
| Beta | 0.08 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| SLXNW | S&P500 | |
| Current price drop from All-time high | -97.15% | -1.46% |
| Highest price drop | -98.40% | -56.47% |
| Date of highest drop | 28 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -77.38% | -10.99% |
| Avg time to new high | 58 days | 12 days |
| Max time to new high | 644 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Employees
11
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner